Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients

Keyphrases

• Hepatocellular Carcinoma 100%
• Hepatitis C 100%
• Targeted Proteomics 100%
• Infected Patients 100%
• Selected Reaction Monitoring 100%
• Biomarker Validation 100%
• Biomarker Discovery 100%
• Therapeutic Intervention 66%
• Dynamic Range 66%
• Quantitative Verification 66%
• Early Detection 33%
• Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 33%
• Disease States 33%
• Minimally Invasive 33%
• High Risk 33%
• Diagnostic Tool 33%
• Clinical Validation 33%
• Rate Limiting 33%
• Biomarker Panel 33%
• High Probability 33%
• Serum Proteins 33%
• Early Cancer Detection 33%
• Unmet Medical Need 33%
• Serum Biomarkers 33%
• Body Fluids 33%
• Multiplexing 33%
• Mass Spectrometry Methods 33%
• Specific Biomarkers 33%
• Simultaneous Analysis 33%
• Tandem Mass Spectrometry 33%
• Patient Cohort 33%
• Proteomic Profiling 33%
• Comparative Proteomics 33%
• Complex Mixtures 33%
• Two-dimensional Difference Gel Electrophoresis 33%
• I-gel 33%
• Depletion Method 33%
• Machine Learning Approach 33%
• Acute Hepatitis C 33%
• Targeting Peptide 33%
• Compress 33%
• Hepatocellular Carcinoma Patients 33%
• Sensitive Biomarker 33%
• Enrichment Method 33%
• Support Vector Machine Learning 33%
• Reaction Dynamics 33%
• Early Disease Detection 33%
• Early Hepatocellular Carcinoma 33%
• Procedural Risk 33%
• Proteome Complexity 33%
• Dynamic multiple Reaction Monitoring (dMRM) 33%
• Protein Enrichment 33%

Biochemistry, Genetics and Molecular Biology

• Proteomics 100%
• Biomarker Validation 100%
• Selected Reaction Monitoring 100%
• Biomarker Discovery 100%
• Liquid 33%
• Hepatitis C Virus 33%
• Monospecific Antibody 33%
• Mass Spectrometry 33%
• Proteome 33%
• Support Vector Machine 33%
• Serum Total Protein 33%
• Gel Electrophoresis 33%
• Tandem Mass Spectrometry 33%
• Target Peptide 33%